Dr. Kingsley is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
3730 S Eastern Ave
Las Vegas, NV 89169Phone+1 702-952-3400Fax+1 702-952-3461
Education & Training
University of Arizona College of Medicine-TucsonFellowship, Hematology and Medical Oncology, 1983 - 1985- University of Arizona College of Medicine-TucsonResidency, Internal Medicine, 1980 - 1983
University of Utah School of MedicineClass of 1980
Certifications & Licensure
NV State Medical License 1985 - 2025
AZ State Medical License 1981 - 2020
UT State Medical License 1985 - 1986- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Top MD Consumers Checkbook
Clinical Trials
- Efficacy and Safety of Idelalisib (GS-1101) in Combination With Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas Start of enrollment: 2013 Jan 16
- Ibrutinib in Combination With Lenalidomide and Rituximab in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma Start of enrollment: 2014 Mar 13
- A Study of Zanubrutinib (BGB-3111) Versus Ibrutinib in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia Start of enrollment: 2018 Nov 01
- Join now to see all
Publications & Presentations
PubMed
- 31 citationsZanubrutinib in patients with previously treated B-cell malignancies intolerant of previous Bruton tyrosine kinase inhibitors in the USA: a phase 2, open-label, single...Mazyar Shadman, Ian W Flinn, Moshe Y Levy, Ryan F Porter, John M Burke
The Lancet. Haematology. 2023-01-01 - 95 citationsIbrutinib plus lenalidomide and rituximab has promising activity in relapsed/refractory non-germinal center B-cell-like DLBCLAndre Goy, Radhakrishnan Ramchandren, Nilanjan Ghosh, Javier Munoz, David S. Morgan
Blood. 2019-09-26 - 10 citationsROSEWOOD: A Phase II Randomized Study of Zanubrutinib Plus Obinutuzumab Versus Obinutuzumab Monotherapy in Patients With Relapsed or Refractory Follicular Lymphoma.Pier Luigi Zinzani, Jiří Mayer, Christopher R Flowers, Fontanet Bijou, Ana C De Oliveira
Journal of Clinical Oncology. 2023-11-20
Press Mentions
Introducing Vegas Inc’s 2021 Top DoctorsAugust 26th, 2021- Health Care Quarterly’s 2020 Top DoctorsAugust 20th, 2020
- Top Doctors 2020August 1st, 2020
- Join now to see all
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
